Taysha Gene Therapies to present TSHA-102 data at 2026 Rett meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026 4:01 PM EDTRecently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through 12 months post-TSHA-102 regardless of age or disease severity
Rett syndrome natural history data analysis shows a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial
New data support the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies
Preclinical data demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded, supporting effective... More
